Evaluating the Efficacy of Oral Semaglutide in Chinese Patients with Type 2 Diabetes by Baseline Characteristics-Post Hoc Analysis of PIONEER 11 and 12

被引：0
|
作者：
Ji, Linong
Yuan, Guoyue
Liu, Jun
Zhang, Bingjie
Liu, Wenyan
Shen, Zewei
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-752-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
752-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5
    Mosenzon, Ofri
    Rosenlund, Signe
    Eriksson, Jan W.
    Heller, Simon R.
    Pratley, Richard E.
    Sathyapalan, Thozhukat
    Blicher, Thalia Marie
    Hels, Ole H., Sr.
    Desouza, Cyrus
    DIABETES, 2019, 68
  • [32] Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
    Zinman, Bernard
    Aroda, Vanita R.
    Buse, John B.
    Cariou, Bertrand
    Harris, Stewart B.
    Hoff, Soren Tetens
    Pedersen, Karen Boje
    Tarp-Johansen, Mads Jeppe
    Araki, Eiichi
    DIABETES CARE, 2019, 42 (12) : 2262 - 2271
  • [33] Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study
    Zhou, Lingli
    Cai, Xiaoling
    Luo, Yingying
    Zhang, Fang
    Ji, Linong
    JOURNAL OF DIABETES RESEARCH, 2019, 2019
  • [34] Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis
    Meier, Juris J.
    Bardtrum, Lars
    Cheng, Alice Y. Y.
    Malling, Brian
    Montanya, Eduard
    Wagner, Lily
    Pratley, Richard E.
    DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 1130 - 1135
  • [35] Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
    Peter Rossing
    Stephen C. Bain
    Heidrun Bosch-Traberg
    Ekaterina Sokareva
    Hiddo J. L. Heerspink
    Søren Rasmussen
    Linda G. Mellbin
    Cardiovascular Diabetology, 22
  • [36] Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
    Rossing, Peter
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Sokareva, Ekaterina
    Heerspink, Hiddo J. L.
    Rasmussen, Soren
    Mellbin, Linda G.
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [37] Semaglutide Improves eGFR Slope vs. Placebo Regardless of Baseline HbA1c and Blood Pressure in People With Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Cherney, David
    Bosch-Traberg, Heidrun
    Hadjadj, Samy
    Kuhlman, Anja B.
    Rasmussen, Soren
    Tuttle, Katherine R.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 675 - 675
  • [38] Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
    Bain, S.
    Rea, R.
    Warren, M.
    Holst, A. G.
    Vrazic, H.
    Madsbad, S.
    EUROPEAN HEART JOURNAL, 2018, 39 : 598 - 598
  • [39] Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
    Li, Aihua
    Su, Xiaorong
    Hu, Shanshan
    Wang, Yong
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 198
  • [40] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Patel, Hiren
    Munir, Kashif
    Sutherland, Sindee
    Karanikas, Chrisanthi A.
    Konig, Manige
    DIABETES THERAPY, 2019, 10 (06) : 2321 - 2330
12345